u/Just-Cut-8474

Conexeu unveiled their lead clinical application alongside the listing announcement. It's called B.R.E.A.S.T. — Bioregenerative Ergonomically Architected Smart Tissue — a 3D-bioprinted regenerative breast matrix designed for post-mastectomy reconstruction.

The problem it's targeting: More than 100,000 women undergo mastectomies annually in the US. A significant portion elect not to pursue reconstruction. Existing options are primarily permanent implants or traditional reconstruction approaches. The Conexeu pitch is a resorbable scaffold — a temporary matrix that gradually breaks down as the patient's own tissue grows in to replace it.

The mechanism: Built on the CXU platform, the matrix is designed to function as a structural scaffold that supports the body's regenerative process rather than serving as a permanent replacement. The company describes this as a paradigm shift from permanent implant approaches.

What's actually been demonstrated: Preclinical data only at this stage. No human data on the B.R.E.A.S.T. product has been disclosed. The broader CXU platform has over a decade of university preclinical research behind it, but preclinical results and human outcomes are different questions entirely.

Regulatory path: The company is pursuing a predicate-based 510(k) strategy for its initial indication with submission planned for early 2027. A 510(k) clearance pathway is faster than a full PMA (Premarket Approval) but requires demonstrating substantial equivalence to an existing cleared device. Which specific predicate they're targeting isn't disclosed in current public materials.

This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - 1, 2, 3

Conexeu unveiled their lead clinical application alongside the listing announcement. It's called B.R.E.A.S.T. — Bioregenerative Ergonomically Architected Smart Tissue — a 3D-bioprinted regenerative breast matrix designed for post-mastectomy reconstruction.

The problem it's targeting: More than 100,000 women undergo mastectomies annually in the US. A significant portion elect not to pursue reconstruction. Existing options are primarily permanent implants or traditional reconstruction approaches. The Conexeu pitch is a resorbable scaffold — a temporary matrix that gradually breaks down as the patient's own tissue grows in to replace it.

The mechanism: Built on the CXU platform, the matrix is designed to function as a structural scaffold that supports the body's regenerative process rather than serving as a permanent replacement. The company describes this as a paradigm shift from permanent implant approaches.

What's actually been demonstrated: Preclinical data only at this stage. No human data on the B.R.E.A.S.T. product has been disclosed. The broader CXU platform has over a decade of university preclinical research behind it, but preclinical results and human outcomes are different questions entirely.

Regulatory path: The company is pursuing a predicate-based 510(k) strategy for its initial indication with submission planned for early 2027. A 510(k) clearance pathway is faster than a full PMA (Premarket Approval) but requires demonstrating substantial equivalence to an existing cleared device. Which specific predicate they're targeting isn't disclosed in current public materials.

This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - 1, 2, 3

Brand new listing as of today, May 21, 2026. Conexeu Sciences (CNXU) is a preclinical-stage regenerative tissue platform company. Here's what's actually known on day one.

What they are: A biotech built around a proprietary extracellular matrix (ECM) platform called CXU. The platform is designed to restore soft tissue lost through injury, aging, or weight loss. One formula, one device architecture intended to scale across multiple indications without reformulation.

What exists today:

• Lead product: Ten Minute Tissue — an injectable ECM that stays fluid at room temperature and transitions to a stable gel inside the body within roughly ten minutes
• Preclinical data showing scaffold formation, organized healing dynamics, and low inflammatory profile
• IP protected by issued patents in the US, EU, Japan, and Australia with additional filings pending
• No royalty or licensing obligations — company owns the IP outright

What doesn't exist yet:

• No FDA clearance
• No human clinical data
• 510(k) submission planned for early 2027 for the initial indication
• No revenue

Share structure: 25,269,996 shares outstanding, 35,238,222 fully diluted. The gap between those two numbers — roughly 10M shares — represents warrants or options outstanding. Worth tracking as a dilution factor.

H.C. Wainwright acted as financial advisor on the listing.

This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - 1, 2, 3

Brand new listing as of today, May 21, 2026. Conexeu Sciences (CNXU) is a preclinical-stage regenerative tissue platform company. Here's what's actually known on day one.

What they are: A biotech built around a proprietary extracellular matrix (ECM) platform called CXU. The platform is designed to restore soft tissue lost through injury, aging, or weight loss. One formula, one device architecture intended to scale across multiple indications without reformulation.

What exists today:

• Lead product: Ten Minute Tissue — an injectable ECM that stays fluid at room temperature and transitions to a stable gel inside the body within roughly ten minutes
• Preclinical data showing scaffold formation, organized healing dynamics, and low inflammatory profile
• IP protected by issued patents in the US, EU, Japan, and Australia with additional filings pending
• No royalty or licensing obligations — company owns the IP outright

What doesn't exist yet:

• No FDA clearance
• No human clinical data
• 510(k) submission planned for early 2027 for the initial indication
• No revenue

Share structure: 25,269,996 shares outstanding, 35,238,222 fully diluted. The gap between those two numbers — roughly 10M shares — represents warrants or options outstanding. Worth tracking as a dilution factor.

H.C. Wainwright acted as financial advisor on the listing.

This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - 1, 2, 3

Cue Biopharma has quietly undergone a fairly significant strategic repositioning over the past few months. The pipeline looks different than it did a year ago and it's worth understanding what changed and why.

What's gone: The CUE-100 series — the company's previous lead oncology program — is effectively wound down. R&D expenses dropped partly because clinical costs for that series decreased. The Ono Pharmaceutical collaboration agreement that was generating revenue in early 2025 was terminated in March 2025. The prior strategic direction is largely off the table.

What's new:

CUE-221 is now the lead asset. This was formerly known as Ascendant-221 and was brought in through an exclusive license from Ascendant Health Sciences. It's described as a novel anti-IgE antibody with a dual mechanism of action, currently in Phase 2 development for allergic diseases. Anti-IgE is a validated target — omalizumab (Xolair) is the established drug in this space — so the mechanism isn't speculative. The differentiation argument would rest on the dual mechanism and any clinical differentiation from existing options. The data that will inform the global Phase 2b decision is coming from an ongoing China Phase 2 study in Chronic Spontaneous Urticaria, with results expected in the second half of 2026.

CUE-401 is the second program. This is a bifunctional IL-2 and TGF-B candidate targeting autoimmune disease, designed to induce immune tolerance rather than broad suppression. The company hosted a virtual R&D day on this asset. IND submission to the FDA is expected in the second half of 2026, with Phase 1 first-in-human study expected to begin by year end 2026. This is earlier stage than CUE-221.

The Boehringer Ingelheim relationship: This is worth paying attention to beyond the revenue line. The $7.5M milestone payment received post-quarter was for Boehringer Ingelheim's selection and approval of their first compound for lead optimization under the collaboration agreement. That's a technical milestone that suggests the collaboration is progressing, not stalling. How much additional milestone potential remains under that agreement isn't fully detailed in public materials but it's a non-trivial external validation that the underlying platform has commercial partners paying attention.

The new CEO: Shao-Lee Lin, M.D., Ph.D. was appointed President and CEO. The prior leadership team had been running a different strategic direction. Her background is described as 25 years in immunology with experience building multi-billion dollar portfolios and taking a company from inception to IPO. The pivot to allergic and autoimmune disease with a new CEO suggests a deliberate reset rather than incremental adjustment.

This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - 1, 2, 3

Quick breakdown of what actually changed in the Cue Biopharma Q1 report.

The numbers:

• Revenue: $5.7M vs $0.4M in Q1 2025 — significant jump but entirely from the Boehringer Ingelheim collaboration milestone, not product revenue
• R&D expenses: $6.9M vs $8.5M prior year — down $1.6M, primarily due to lower CUE-100 series clinical costs and headcount attrition
• G&A expenses: $4.2M — flat year over year
• Net loss: $5.2M vs $12.3M prior year — materially narrower
• Cash as of March 31: $16.4M, down from $27.1M at year end 2025

The important context on cash: The March 31 figure is somewhat misleading in isolation. Subsequent to quarter end the company completed a $30M private placement and received a $7.5M milestone payment from Boehringer Ingelheim. Pro forma cash position is therefore closer to $54M before expenses. That's a meaningfully different runway picture than $16.4M suggests on its face.

Also worth noting: A 1-for-30 reverse stock split was effective April 23, 2026. All per share figures in the filing have been retroactively restated to reflect this. The EPS loss of $1.08 per share for Q1 is post-split math, not a new deterioration in per-share economics.

This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - 1, 2, 3

Quick breakdown of the Gain Therapeutics Q1 report that dropped May 11.

The numbers:

• Net loss: $5.6M vs $4.5M in Q1 2025 — loss is widening year over year
• EPS loss: $0.13 vs consensus estimate of $0.14 — beat by a penny
• R&D spend: $2.8M vs $2.3M prior year — up $0.5M
• G&A spend: $2.6M vs $2.1M prior year — up $0.5M
• Cash position: $16.5M as of March 31, down from $20.8M at year end 2025

The math on cash runway: They burned roughly $4.3M in Q1. At that rate, $16.5M gets them somewhere around 3-4 quarters of runway. They have explicitly flagged going concern risk in prior filings. Phase 2 is expected to begin Q3 2026 — which will accelerate the burn. A capital raise before or alongside Phase 2 initiation seems likely.

What the stock did: Up ~3.4% premarket on the Q1 print. The beat was marginal — one cent better than consensus — so the move was probably more about Phase 2 timeline confirmation than the financial result itself.

This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - 1, 2, 3

Been looking at a few Parkinson’s-focused biotechs and laid them out a bit differently to compare where the risk actually sits.

Gain Therapeutics (GANX)

Stage: Early (Phase 1b)

What stands out: GT-02287 showing early biomarker movement + some motor stabilization signals

Support: Backed by the Michael J. Fox Foundation

Financials: No revenue, ~ $20M annual burn

Watchouts: Likely needs to raise before Phase 2

Timeline: Phase 2 expected Q3

Market cap: ~ $88M

Annovis Bio (ANVS)

Stage: Late (Phase 3 for Alzheimer’s, Parkinson’s study ongoing)

What stands out: Closest to a potential inflection point

Financials: No revenue, ~ $28.9M net loss

Watchouts: CFO departure, going concern flags, tight runway

Market cap: ~ $64M

Anavex Life Sciences (AVXL)

Stage: Mid to late, broader CNS pipeline

What stands out: Stronger balance sheet, multiple indications

Financials: ~ $131.7M cash, no debt, multi-year runway

Watchouts: Regulatory setbacks (including negative CHMP opinion)

Market cap: ~ $324M

Quick read:

GANX = early + capital risk

ANVS = late-stage + execution risk

AVXL = funded + regulatory risk

Same theme, three very different ways it can break. 1, 2, 3

Not fully there yet, but the numbers show some incremental movement.

GPO Plus (GPOX) reported revenue of about $4.7M with gross profit around $1.13M, pointing to some improvement in margins. At the same time, operating expenses remain above $4.3M, which keeps pressure on the overall model.

Loss from operations sits around $3.2M, with net loss roughly $4.3M. So while losses narrowed compared to prior periods, they’re still close to the level of total revenue, and the gap to profitability remains wide.

There has been some cost tightening, which helped reduce losses, but not enough yet to materially change the trajectory. The business still needs either a meaningful increase in revenue or further cost discipline to move toward breakeven.

Liquidity is another factor. Cash levels have been minimal, and operations have been supported through notes and equity, which adds another layer to the story going forward.

The direction is improving in parts, but the scale and funding side are still open questions. 1, 2, 3

Ignoring the obvious plug of "hey this is why I should have a ballroom" how obvious is it that it's staged? I haven't been able to find the video anywhere but everyone that talks about it has mentioned it's staged but nobody has said why.